Immunotherapy for non-small cell lung cancer: Are we on the cusp of a new era?

Expert Review of Clinical Immunology

Volumn 11, Issue 8, 2015, Pages 871-873

  Waqar, Saiama N ^a   Morgensztern, Daniel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

immunotherapy; nivolumab; non small cell lung cancer; PD 1; PDL 1

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; MONOCLONAL ANTIBODY;

CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; HUMAN; NON SMALL CELL LUNG CANCER; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG RESISTANCE; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; UNITED STATES;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; UNITED STATES;

EID: 84937203790     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/1744666X.2015.1054374     Document Type: Review

References (14)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29
2. Morgensztern D, Ng SH, Gao F, Govindan R. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 2010; 5: 29-33
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-57
4. Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 2167-77
5. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371: 1963-71
6. Hanna N, Shepherd FA, Fossella FV, et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97
7. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64
8. Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter Phase II study. J Clin Oncol 2012; 30: 2046-54
9. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-54
10. Antonia SJ, Gettinger SN, Chow LQM, et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. ASCO Meeting Abstracts 2014; 32: 8023
11. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-7
12. Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2014; 32: 8020
13. Gandhi L, Balmanoukian A, Hui R, et al. Abstract CT105: MK-3475 (anti-PD- 1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression. Cancer Research 2014; 74: CT105
14. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015; 16: 257-65